Skip Navigation

Study Questions Link Between Side Effects of Nexium, Prilosec and Stomach Cancer

Study Questions Link Between Side Effects of Nexium, Prilosec and Stomach Cancer

Despite concerns in recent years, European researchers published a new study indicating they found no link between popular heartburn drugs like Nexium and Prilosec and an increased risk of stomach cancer.

The drugs belong to a class of medications known as proton pump inhibitors (PPIs), which are widely used to reduce stomach acid and to treat conditions like heartburn, ulcers and gastroesophageal reflux disease (GERD). They work by blocking the proton pumps in the stomach’s lining that produce acid, and are available in prescription and over-the-counter versions.

However, in 2017 researchers from Hong Kong published a study in the medical journal Gut, which suggested that the long-term use of proton pump inhibitors could increase the risk of gastric cancer after treatment for Helicobacter pylori infections. That same year, Swedish researchers found that maintenance use of PPIs was linked to triple the risk of gastric cancer when compared to their peers.

The new study, published in The BMJ on January 21, raises questions about those findings, following an examination of PPI use in five Nordic countries, including Denmark, Finland, Iceland, Norway and Sweden.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

Led by Professor Jasper Lagergren, of the Karolinska Institutet and Karolinska University Hospital, researchers looked at all healthcare patients in the five Nordic countries from 1994 to 2000. They matched each patient with a gastric adenocarcinoma diagnosis with 10 control participants based on similar age, sex, year and country. The team then looked for evidence that linked the gastric cancer diagnoses with PPI use as well as use of histamine-2-receptor antagonists like Pepcid AC and Tagamet.

The researchers found 17,232 cases of gastric adenocarcinoma. However, according to the findings, there was no association between the use of drugs like Prilosec, Nexium and Prevacid, and an increased risk of stomach cancer.

In addition to finding no correlation between PPI use and stomach cancer, the researchers indicated they found several factors which may have led previous studies to the opposite conclusions.

“Multiple sources of error that led to a false positive association were identified—inclusion of proton pump inhibitor use shortly before the gastric adenocarcinoma diagnosis, short term use of proton pump inhibitors, cardia adenocarcinoma, and lack of adjustment for Helicobacter pylori related variables.”

– Professor Jasper Lagergren, Long term use of proton pump inhibitors and risk of stomach cancer: population based case-control study in five Nordic countries

The researchers concluded that despite fears which have circulated through the medical community since at least the 1980s,  “long term proton pump inhibitor use may not be associated with any increased risk of developing gastric non-cardia adenocarcinoma.”

PPI Stomach Cancer Lawsuits

While most consumers believe PPIs are safe and carry few serious health risks, a growing number of lawsuits have been filed in recent years, which allege that important safety information and warnings have been withheld from users and the medical community.

There are currently more than 11,000 Nexium lawsuits, Prilosec lawsuits and other claims brought throughout the federal court system against AstraZeneca, Merck & Co., Procter & Gamble and other manufacturers of PPI-based drugs, which are consolidated as part of a multidistrict litigation (MDL) before U.S. District Judge Claire C. Cecchi in the District of New Jersey.

Much of the litigation involves allegations that the pharmaceutical companies failed to warn about serious kidney risks associated with Nexium and Prilosec, including acute kidney injury, chronic kidney disease and end state renal failure. However, a number of gastric cancer lawsuits have also been filed, many of which involve wrongful death allegations.

Sign up for more health and legal news that could affect you or your family.

Written By: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.



0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

As Bard PowerPort litigation nears its first bellwether trials, the prospect of major jury verdicts over catheter fracture, migration and infection injuries is increasing speculation that settlement talks may intensify, following earlier claims that Becton Dickinson says were resolved in about 18 months before consolidation into a federal MDL.